
Breakthroughs that
See news releases about Etira, our stellar team,


ERX-315 introduced at SABCS 2023
NewsSan Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms…

Independent validation of LIPA as a molecular target in TNBC
NewsDallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany.
The authors conclude that LIPA-activity is a novel…

One year later, highest almetric score for any paper published in Nature Cancer!
News Dallas, Texas. June 1, 2023:
One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid…

Positive preclinical data presented at AACR 2023
News Dallas, Texas. April 18, 2023:
Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented…

Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
NewsDallas, Texas. April 17, 2023:We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of…
Where to find us
Boston Office:
75 Kneeland Ave, 14th Floor
Boston. MA. 02111
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247